LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM.

LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM.

L-SelenoMethionine is a major natural food-form of selenium.

LSN3154567 is a novel inhibitor of NAMPT with IC50 of 18 nM (NCI-H1155 cell), 49 nM (Calu-6 cell), 333 nM (HCC1937 cell), and 389 nM (MCF-7 cell), respectively.

LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively.

LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM.

LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM.

This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.

The product is discontinued. LTX-401 (LTX401) is an oncolytic amino acid derivative with potential immunogenic properties, selectively destroys the structure of the Golgi apparatus.

Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM.

Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells.

LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor, enhance Emax but without affecting agonist potency.

LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation.

Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM).

Lurasidone is a novel psychotropic agent that has been shown in studies of cloned human receptors to be an antagonist at the 5-HT2A receptor.

Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position.

Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.

LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays.

LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally.

LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

LX-2931 (LX2931) is a potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor.

LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.

LY 2318912 is a potent, competitive, small molecule inhibitor of anandamide uptake with IC50 of 7.27 nM, shows high affinity against anandamide transporter binding site with Kd o f7.62 nM.

LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

LY 392098 is a selective, potent and centrally active positive allosteric modulator of AMPAR.

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.

LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM).

LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor.

LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM).

LY2584702 is a potent, selective, ATP-competitive inhibitor of P70 S6 kinase-1 (p70S6K1) with IC50 of 4 nM.

LY2584702 is a potent, selective, ATP-competitive inhibitor of P70S6 kinase-1 (p70S6K1) with IC50 of 4 nM.

LY2623091 (LY-2623091) is an orally administered mineralocorticoid receptor antagonist for the treatment of essential hypertension and chronic kidney disease..

LY2624803 is a novel potent histamine H1 and 5HT-2A receptor modulator in the pipeline for treating insomnia..

LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.

LY2794193 is a highly potent and selective mGlu3 receptor agonist with Ki of 0.93 nM and EC50 of 47 nM, >100-fold selectivity over mGlu2 receptor..

LY2857785 is a potenrt, reversible and ATP-competitive CDK9 inhibitor with IC50 of 11 nM, also inhibits CDK8 (IC50=16 nM) and weakly inhibits CSK7 (IC50=246 nM).

LY2922470 (LY-2922470) is a potent, selective, orally available GPR40 agonist with EC50 of 7 nM.

LY2979165 (MP-101) is the alanine prodrug of LY2812223, a selective orthosteric mGlu2 receptor agonist.

LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.

LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.

LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.

LY305 (LY-305) is a non-steroidal selective androgen receptor modulator (SARM) with Ki of 2.03 nM, demonstrates potent agonist activity in the aforementioned C2C12 cellular assay (EC50=0.499 nM).

LY3130481 (CERC611) is a potent, selective, noncompetitive TARP γ8-associated AMPA receptors with IC50 of 65.3 nM (GluA1/TARP γ-8), with no activity for γ-2 (cerebellum) or other TARP members.

LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively..

LY320135 is a selective cannabinoid (CB) receptor 1 antagonist (Kis = 224 and >10,000 nM for CB1 and CB2, respectively, in vitro).

LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease..

LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.

LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively.

LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor.

LY-345899 (LY345899) is a novel potent, cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with IC50 of 96 nM and 663 nM, respectively; MTHFD2 is a novel target for drug development.

LY354740 is an agonist of the group II metabotropic glutamate receptor (mGluR) subtypes mGluR2 and mGluR3 (Kis = 99 and 94 nM, respectively).

LY379196 is a highly specific PKCβ inhibitor with IC50 of 30-50 nM for PKCβI and PKCβII, displays >10-fold selectivity of PKCα, δ, η, and γ (>600 nM).

LY-404187 is a potent, selective, positive allosteric modulator of AMPA receptor (AMPAR) with EC50 of 1.3 uM.

LY-487379 is a potent, selective positive allosteric modulator of mGluR2 (EC50=0.27 uM) without activity at mGluR3; shows no intrinsic agonist or antagonist activity at hmGluR2, markedly potentiates glutamate-stimulated [35S]GTPgammaS binding at hmGluR2; potentiates synaptically evoked mGluR2 responses in rat hippocampal slices, modulates excitatory synaptic transmission in the rat globus pallidus.

LY-487379 is a potent, selective positive allosteric modulator of mGluR2 (EC50=0.27 uM) without activity at mGluR3.

LY500307 is a potent, selective estrogen receptor β agonist with EC50 of 0.66 nM, 32-fold selectivity against estrogen receptor α. Phase 2.

LY-503430 is a novel AMPA receptor (AMPAR) potentiator that selectively enhances glutamate-induced calcium influx into HEK293 cells transfected with human GLUA1, GLUA2, GLUA3, or GLUA4 AMPA receptors with EC50 of 0.1-4 uM.

LY-83583 is an inhibitor of soluble guanylate cyclase (sGC) and of cGMP production, inhibits sGC in human platelets with IC50 of 2 uM.

Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor..

LYPLAL1-IN-11 is a potent, selective, covalent inhibitor of lysophospholipase-like 1 (LYPLAL1) with IC50 of 6 nM.

Lys01 trihydrochloride (Lys05) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.

LYS228 is a novel potent monobactam that shows potent activity against carbapenem-resistant isolates of Enterobacteriaceae with MIC90 of 2 ug/ml.

LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site.

L-α-Hydroxyglutaric acid disodium salt (L-2-Hydroxyglutarate.

M-110 is a potent, selective inhibitor of PIM kinase family with preference for PIM-3 with IC50 of 0.047, 2.5 and 2.5 uM for PIM3, PIM1 and PIM2, respectively.

M4284 (M-4284) is a high-affinity biphenyl mannoside FimH inhibitor with HAI of 16 nM in hemagglutination assay.

M-525 is a first-in-class, highly potent, irreversible small-molecule inhibitor of the menin-MLL interaction with binding IC50 of 3.3 nM in FP assays.

MAC1 (Monastrol Antagonizing Compound 1) is a small molecule that can rescue spindle bipolarity in cells lacking Eg5 activity.

MAC13772 is a potent inhibitor of BioA with an IC50 of 250 nM, a novel antibacterial inhibitor that selectively inhibits PABA biosynthesis in M tuberculosis..

MAC168425 is a novel antibacterial inhibitor that interferes with glycine metabolism in E coli..

MAC173979 is a novel time-dependent inhibitor of p-aminobenzoic acid biosynthesis with IC50 of 30 uM, represents the first PABA biosynthesis inhibitor with activity against Gram-negative bacteria..

Macranthoidin B is a major bioactive saponin in rat plasma after oral administration of extraction of saponins from Flos Lonicerae.

MAI-150 is a peptidomimetic inhibitor of APC-Asef interaction, blocks colorectal cancer migration..

MAI-400 (MAI400) is a novel peptide inhibitor of APC-Asef interaction with Kd of 12 nM and IC50 of 0.25 uM.

MAL3-101 is a Hsc70 modulator that inhibits Hsp70 ATPase activity, exhibits antiproliferative activity in breast cancer cells SK-BR-3 with IC50 of 27 uM.

MALAT1 inhibitor 5 (Malat1 inhibitor 5) is a selective small molecule targeting of Metastasis-associated lung adenocarcinoma transcript 1 (Malat1/MALAT1 mouse/human), a highly conserved long non-coding RNA; does not affect Neat1 lncRNA levels.

MALT1 paracaspase inhibitor 3 is a potent, specific, covalent inhibitor of MALT1 paracaspase with Ki of 10 nM, exhibits 10-and 100-fold improved potency in vitro and in vivo compared with Z-VRPR-fmk.

Maltitol is a sugar alcohol used as a sugar substitute. It has 75-90% of the sweetness of sucrose (table sugar) and nearly identical properties. Maltitol may also be used as a plasticizer in gelatin capsules, as an emollient, and as a humectant.

Maltohexaose is a natural saccharide, and can be produced from amylose, amylopectin and whole starch.

Maltopentaose is the shortest chain oligosaccharide that can be classified as maltodextrin and is also used in a study to investigate glycation and phosphorylation of α-lactalbumin.

Manidipine is a dihydropyridine L- and T-type calcium channel blocker.

MAP4K4-IN-17 is a potent and highly selective MAP4K4 inhibitor with IC50 of 14.9 nM, showes improved overall drug-like properties compared to PF-06260933.

MAP4K4-IN-37 is a potent, selective, orally active inhibitor of serine-threonine kinase MAP4K4 with IC50 of 0.4 nM.

MAP4K4-IN-44 is a potent, moderately selective small molecule MAP4K4 inhibitor with IC50 of 5 nM in LC3K assay, demonstrates favorable in vivo bioavailability in mouse..

Mapracorat (ZK 245186) is a potent, selective and non-steroid glucocorticoid receptor (GR) agonist with binding Ki of 1.9 nM.

Marbostat-100 is a potent, selective HDAC6 inhibitor with Ki of 0.7 nM, displays >200-fold selectivity over HDAC1-5, and HDAC7-10.

Maribavir(GW257406X; BW1263W94; 1263W94) inhibits HCMV replication is by inhibition of an HCMV encoded protein kinase enzyme called UL97 or pUL97.

Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor

Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.

Maropitant citrate (Cerenia) is a selective neurokinin 1 receptor (NK1) antagonist for prevention of vomiting due to motion sickness in dogs..

Maropitant is a neurokinin (NK1) receptor antagonist.

MARPIN is a novel ATR-Chk1 pathway inhibitor that inhibits hydroxyurea (HU)-induced phosphorylation of Ser345 on Chk1 with IC50 of 7.7 uM.

Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2. Science 20 Jul 2021: eabg5827 DOI: 10.1126/science.abg5827

MB-07811 (VK-2809) is an orally bioavailable, liver-targeted prodrug of MB07344, which is a thyroid hormone receptor-beta agonist (TRβ) agonist, efficiently converted to MB07344 by liver microsomes in vivo.

MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro..

MB725 is a small-molecule p53 mutant Y220C stabilizer, induces selective viability reduction in several p53-Y220C cancer cell lines (Huh7 cell IC50=10 uM).

MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.

MC-1575 is a potent and selective class IIa HDAC inhibitor with IC50 of 440 nM for maize HD1-A, displays >70-fold selectivity over HD1-B.

MC2884 is a novel hybrid, dual HAT/EZH2 inhibitor with IC50 of 3.27, 8.35 and 4.56 uM for CBP, KAT5 and p300, respectively.

Mca-DEVDAPK(Dnp)-OH is a substrate for caspase-3.

Mca-PL is a fluorogenic peptide that has been used as a building block in the synthesis of Mca-PLGL-Dpa-AR-NH2, a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-7.

MCB-613 is a novel and potent stimulator of p160 steroid receptor coactivators (SRCs). It is a Pan-SRCs stimulator.

Netoglitazone, also known as isaglitazone and MCC-555, is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Netoglitazone exerts both peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist activity. Netoglitazone decreases bone formation and increases marrow adipocyte formation in vivo.MCC 555 (Isaglitazone.

MCL0129 is a selective, potent melanocortin-4 receptor (MC4R) antagonist with Ki of 7.9 nM, without affinity for MC1 and MC3.

Mcl1-IN-2 is an Mcl-1 inhibitor without a reported IC50 value..

Mcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA), reduces multiple cancer cells and inhibits PUMA-mediated apoptosis.

MCOPPB 3Hcl is a nociceptin receptor agonist with pKi of 10.07; weaker activity at other opioid receptors.

MCP110 is a potent Ras/Raf-1 interaction inhibitor.

MCT1-IN-4a is a potent, selective monocarboxylate transporter 1 (MCT1) inhibitor with IC50 of 90 nM.

MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.

MDI-2268 (MDI2268) is a small-molecule, in vivo-active inhibitor of plasminogen activator inhibitor type-1 (PAI-1), demonstrates excellent pharmacokinetics, potent activity against vitronectin-bound PAI-1 in vivo, and efficacy in murine model of venous thrombosis.

Meayamycin is an analogue of FR901464 that binds to the splicing factor 3b (SF3b) complex and inhibits pre-mRNA splicing, shows picomolar antiproliferative activity against various cancer cell lines and multidrug-resistant cells..

Mebendazole is a synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking g

Meclizine is a histamine H1 receptor antagonist used to treat nausea and motion sickness.

Mefuparib(CVL218) hydrochloride is a potent, highly selective, competitive PARP1/2 inhibitor with IC50 of 3.2/1.9 nM, respectively.CVL218 was more potent than Remdesivir in blocking Coronavirus infection of cells and equally as potent as Remdesivir in blocking replication of virus once it has entered the cells.

Melagatran is a synthetic, small-peptide direct thrombin inhibitor with anticoagulant activity.

Dersimelagon, also known as MT-7117 and WHO 10832, is a novel, orally-administered, small molecule, selective melanocortin-1 receptor (MC1R) agonist that increases skin melanin without sun exposure and is being developed to increase light tolerance in EPP/XLP patients. Dersimelagon significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial.

Melanocyte-stimulating hormone release-inhibiting factor (MSH-R-IF) is a hypothalamic tripeptide that binds to rat striatum (Kd = 4.69 nM) and has diverse biological activities.

Meleagrin is an antibiotic derived from a deep ocean, penicillin-producingP. chrysogenum.

Melflufen (Melphalan flufenamide, J1) is a novel dipeptide and alkylating prodrug of melphalan, inhibits angiogenesis in vitro and in vivo.

MELK inhibitor 17 is a potent, selective MELK inhibitor with Ki/IC50 of 0.39/3 nM, >100-fold selectivity over CHK1, CAMKK2, NUAK1 and ERK2.

Melphalan(Sarcolysin; L-PAM) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents; attaches the alkyl group to the guanine base of DNA.

Meptazinol Hcl(WY-22811 Hcl) is a unique centrally active opioid analgesic.

Mequitazine is a potent, nonsedative and long-acting histamine H1 antagonist.

Merck60 (BRD 6929, Compound-60) is a potent, selective and brain-penetrant inhibitor of HDAC1 and HDAC2 with IC50 of 1 nM and 8 nM respectively.

Meropenem

meso-Erythritol is a sugar alcohol that occurs naturally in a variety of foods (e.g., pear, watermelon), is 60-80% as sweet as sucrose, and is an approved low-calorie sweetener food additive.

Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.

Metarrestin (ML246) is a specific inhibitor of perinuclear compartment (PNC), disrupts PNCs in PC3M-GFP-PTB cells with IC50 of 0.39 uM, specifically binds eEF1A2.

Metaxalone(AHR438;NSC170959) is a muscle relaxant used to relax muscles.

Metesind glucuronate (AG 331.

MethADP is a specific CD73 inhibitor.

Methoxy-PEPy is a potent, selective mGlu5 receptor antagonist with IC50 of 1 nM.

Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester;Methyl protocatechuate) is a major metabolite of antioxidant polyphenols found in green tea. Antioxidant and anti-inflammatory effect.

Methyl Gerfelin (M-GFN) is an osteoclastogenesis inhibitor (IC50=2.8 uM) through the competitive inhibition of glyoxalase I (GLO1) with Ki of 0.23 uM.

Methyliodobikinin is a potent bikinin-like inhibitor targeting GSK3/Shaggy-like kinase, shows improved cell permeability, highly potent in vivo although it had lower activity in vitro.

Methylnaltrexone Bromide is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.

Methylproamine is a DNA-binding radioprotector which, on the basis of published pulse radiolysis studies, acts by repair of transient radiation-induced oxidative species on DNA.

Metixene hydrochloride hydrate is an anticholinergic antiparkinsonian agent, potently inhibits binding of quinuclidinyl benzilate (QNB) to the muscarinic receptor in rat brain cortical tissue, with an IC50 of 55 nM and a Kd of 15 nM.

Metronidazole Benzoate is the benzoate ester of metronidazole, a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.

MF-094 (MF094) is a potent, highly selective inhibitor of ubiquitin specific protease 30 (USP30) with IC50 of 0.12 uM, demonstrates <30% inhibitory activity for a panel of 22 USPs assays at 10 uM.

MF266-1 is a potent, selective prostaglandin E receptor subtype 1 (EP1) antagonist with Ki of 3.8 nM, displayes a relatively good selectivity over other prostanoid receptors..

MF498 is a novel and selective E prostanoid receptor 4 (EP4) inhibitor, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.

MF-766 (MF766) is a highly potent and selective EP(4) antagonist with binding Ki of 0.23 nM, displays no significant affinity (>7000-fold selectivity) against other PG receptors (IC50>1500 nM); behaved as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay; exhibits blockade of inhibition of TNFa-induced IP10 release by the specific EP4 agonist L-000902688 (IC50=9.5 nM); demonstrates potency and efficacy of in the rat AIA model measuring inhibition of paw swelling.

MFA-1 (Merck FXR agonist 1) is a potent, synthetic FXR agonist with EC50 of 16.9 nM in coactivator recruitment assays, displays 500-fold more potent than CDCA.

MFN2 agonist B-A/l is a mall-molecule mimics of the peptide-peptide interface of MFN2, allosterically activates MFN2 and promotes mitochondrial fusion with EC50 of 3 nM.

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2.

MGR1 is a ROS-generating probe that can generate ROS (reactive oxygen species) in different mammalian cells, causes concentration-dependent cell death in HEK293T with IC50 of 5.7 uM..

MGV354 is a novel potent, selective soluble Guanylate Cyclase (sGC) activator, lowers intraocular pressure (IOP) in preclinical models of glaucoma..

MGV354 is a novel potent, selective soluble Guanylate Cyclase (sGC) activator, lowers intraocular pressure (IOP) in preclinical models of glaucoma..

MI 219 is a potent, specific MDM2-p53 inhibitor with Ki of 5 nM, >10,000-fold selective for MDM2 over MDMX.

MI-1481 (MI1481) is a highly potent inhibitor of the menin-MLL1 interaction with IC50 of 3.6 nM, 10-fold increase in inhibitory activity over MI-463 and MI-503.

MI-2-2 hydrochloride is a potent inhibitor of the menin-MLL interaction that binds to menin with low nanomolar affinity (Kd=22 nM).

MI-2-2 is a potent inhibitor of the menin-MLL interaction that binds to menin with low nanomolar affinity (Kd=22 nM); inhibits the interaction of menin with MLL-AF9 in HEK293 cells in a dose-dependent manner with 4-fold potentcy improvement over MI-2; suppresses growth of MLL-AF9–transformed BMCs; causes MV4:11 cells growth inhibition of with GI50 of 3 uM.

MI-223 (NSC 320223) is a small molecule that specifically binds to Mcl-1 with Kd of 160 nM, inhibits HR DNA repair and sensitizes cancer cells to DNA replication agents.

MID-1 (ChemBridge5655896) is a specific small molecule MG53-IRS-1 interaction disruptor (MID), but not MG53-FAK and-Cav-3 interaction; increases the IRS-1 protein level in C2C12 myotubes, abrogates MG53-induced IRS-1 ubiquitination and degradation; potent

Midazolam (Dormicum.

Midodrine is a selective α1-adrenoceptor agonist that acts as a vasopressor/antihypotensive agent for the treatment of dysautonomia and orthostatic hypotension.

Midodrine is a selective α1-adrenoceptor agonist that acts as a vasopressor/antihypotensive agent for the treatment of dysautonomia and orthostatic hypotension.

MIF-IN-3bb is a potent inhibitor of Migration inhibitory factor (MIF) tautomerase activity with Ki of 57 nM.

MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.

Milrinone(Primacor) is a a potent and selective phosphodiesterase 3 inhibitor with an IC50 of 0.42 μM for the inhibition of FIII PDE

Milveterol (GSK 159797) is a potent, selective long-acting β2 adrenoceptor agonist with pEC50 of 10.2 in cell-based assays, displays good β2/β1 selectivity (>300-fold).

Milveterol (GSK 159797) is a potent, selective long-acting β2 adrenoceptor agonist with pEC50 of 10.2 in cell-based assays, displays good β2/β1 selectivity (>300-fold).

MIN-101 (Roluperidone, CYR-101, MT-210) is a higly potent 5-HT2A and sigma 2 receptor antagonist, with no direct dopamine affinities, for treatment of negative symptoms in schizophrenia..

MIND-4 is a novel potent, selective, non-competitive SIRT2 deacetylase inhibitor with IC50 of 1.2 uM, Ki of 2.1 uM, and also is an inducer of the NRF2 pathway.

Minesapride (DSP-6952) is a novel potent, selective, orally active 5-HT4 receptor partial agonist with Ki of 50-100 nM for human 5-HT4a/4b/4c.

MIR17PTi is a novel LNA gapmeR antisense oligonucleotide (LNA-ASO), first-in-class inhibitor of pri-mir-17-92.

miR-21 inhibitor 37 is a novel inhibitor of miR-21 function with EC50 of 5.3 uM in HeLa-miR21-Luc assays, displays no inhibition of miR-122.

miR544-IN-1 (SID 3712249) is a selective small molecule inhibitor of miR-544 biogenesis.

Mirk-IN-1 is a potent, specific inhibitor of Dyrk1B (Mirk kianse) and Dyrk1A with IC50 of 68 nM and 22 nM respectively, shows SW620 cell IC50 of 1.9 uM.

MitoBloCK 1 is a small molecule inhibitor that blocks the import of substrates that use the TIM22 import pathway, but not TIM23 or the Mia40/Erv1 translocation pathways.

MitoBloCK-10 (MB-10) is a potential attenuator of protein import into mitochondria via targeting Tim44, inhibits the import of substrates that use the TIM23 import pathway.

MitoBloCK-11 (MB-11) is a s mall molecule inhibitor of mitochondrial protein import possibly acts through transport protein Seo1, but not Tom70 or Tom20; inhibits precursor proteins that contain hydrophobic segments, confers growth in media lacking uracil in a specific manner and affects zebrafish development.

Mitomycin C is a DNA crosslinking agent that inhibits DNA synthesis and induces apoptosis in a variety of cells.

Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.

MIV-247 (MIV247) is a potent, selective, orally active inhibitor of cathepsin S with Ki of 2.1 nM (human cathepsin S).

MIV-711 (MIV711, MV076159) is a potent, selective cathepsin K inhibitor with Ki of 0.98 nM, displays >1300-fold versus the other human cathepsins.

Mizagliflozin (DSP-3235, KGA-3235, GSK-1614235) is a potent, selective, orally active SGLT1 inhibitor with Ki of 27 nM, displays >350-fold selectivity over SGLT2.

Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.

MJN110 (MJN-110) is a potent, selective, and orally active MAGL inhibitor with IC50 of 2.1 nM (2-AG hydrolysis).

MJN-228 is a selective ligand for the lipid-binding protein nucleobindin 1 (NUCB1) with IC50 of 3.3 uM (blocks AEA-DA probe labeling of NUCB1).

MK-0249 is a novel potent, selective histamine H3 inverse agonist for the treatment of cognitive impairment with schizophrenia..

MK-0343 (MRK-409) is a potent, α2/3 subtype selective, partial GABAA receptor agonist, shows greater agonist efficacy at the α3 over α1 subtypes.

MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.

MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.

MK-0448 is a potent, specific I(Kur) current/Kv1.5 channel inhibitor with IC50 of 8.6 nM, potently inhibits IKur in human atrial myocytes with IC50 of 10.8 nM.

MK-0674 is a potent, selective, reversible and orally active cathepsin K inhibitor with IC50 of 1 nM.

MK-0731 is a potent, selective kinesin spindle protein (KSP) inhibitor with IC50 of 2.2 nM, cell EC50 of 5.3 nM.

MK-0812 is chemokine receptor CCR-2 antagonist

MK-0941 is a novel Glucokinase activator (GKA)

MK-0974(Telcagepant) is a highly potent, selective, and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively; displays >1500-fold lower affinity for the canine and rat receptors

MK1 is a small molecule inducer of megakaryopoiesis (EC90=750 nM) that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes, does not adversely affect erythrocyte differentiation.

MK-1832 is a potent, selective Kv1.5 inhibitor with IC50 of 86 nM, exhibits improved selectivity for IKur over IKs (>3000-fold) compares with MK-0448 (70-fold), also exhibits an improved preclinical pharmacokinetic profile..

MK-1925 is a selective, orally active, brain-penetrant opioid receptor-like 1 (ORL1.

MK-204 is a potent, selective AKR1B10 inhibitor with IC50 of 80 nM, shows high selective (270-fold) over AKR1B1.

MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively.

MK-2894 is a highly potent and selective second generation EP4 antagonist.

MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM.